Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
SPECIAL ANNOUNCEMENT
2016 Photonics Buyers' Guide Clearance! – Use Coupon Code FC16 to save 60%!
share
Email Facebook Twitter Google+ LinkedIn Comments

SurgiLight Seeks Trials of Laser Treatment For Reading Inability

Photonics.com
Oct 2001
ORLANDO, Fla., Oct. 31 -- SurgiLight Inc. has filed an Investigational Device Exemption (IDE) with the Food and Drug Administration (FDA) seeking clearance of a procedure to treat presbyopia. The filing requests the initiation of clinical trials at seven US sites, involving 350 patients. Prior clinical data was collected at four overseas sites, wherein the SurgiLight OptiVision (formerly the IR-3000) Er:YAG laser was employed to remove certain eye tissue. Results showed reversal of the presbyopia condition in nine of every ten eyes of the more than 100 eyes treated, extending up to one year after surgery. This data, together with results from extensive long-term animal studies and acute laboratory studies, is being presented to the FDA for review.


Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.